Nervecentre Software Ltd has been awarded a place on a framework agreement with Digital Health and Care Wales which will see it provide an electronic platform for prescriptions, medicines reconciliation and administration.
The platform will be used in hospitals across the country. It not only saves clinicians time when prescribing and administering medications, but it also improves patient safety.
The solution can help to minimise risks of medication errors, while also enabling clinical decision support to ensure high levels of patient care.
Paul Volkaerts, CEO at Nervecentre Software Ltd, said: “We are delighted to be awarded a place on the Welsh ePMA framework, and we look forward to working together with hospitals and health boards in Wales to introduce this comprehensive ePrescribing programme, helping to make the prescribing, dispensing and administration of medicines everywhere in Wales, easier, safer, more efficient and effective.”
Nervecentre is one of three organisations that are included on the all-Wales ePMA framework. During the tender process it was ranked in first place, achieving full marks for its clinical capabilities.
Nervecentre’s closed-loop e-prescribing and barcode medication administration software (ePMA) is used extensively across four NHS acute trusts in England.
These trusts include: University Hospitals of Leicester NHS Trust; Bedfordshire Hospitals NHS Foundation Trust; Sherwood Forest Hospitals NHS Foundation Trust; and Nottingham University Hospitals NHS Trust.
The ePMA is used in in-patients, maternity, paediatrics and emergency departments, with Nervecentre estimating a million medications a month are prescribed using its ePMA solution.
In addition, it believes as many as 99% of those are administered at the patient’s bedside using an app. The ePMA solution provides full validation against allergies and drug-drug interactions, even when used in mobile form.
The inclusion of Nervecentre on the all-Wales ePMA framework follows on from the all-Wales Hospital Pharmacy system, which was implemented in 2020 as part of plans to modernise pharmacy and prescribing.